The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment

Inclusion Criteria: * patient aged between 18 and 50 years * symptoms consistent with CBP * positive Mears-Stamey test Exclusion Criteria: * patients younger than 18 years * history of neurological disease, urinary stones or cancer * allergy to fluoroquinolones or any components of Butirprost® * post-void residual \> 50 mL * Use of alpha-blockers or 5-alpha-reductase inhibitors (5-ARI) * previous prostatic surgery, antibiotic treatment within four weeks prior to the study * refusal to provide informed consent and incomplete follow-up data * Patients testing positive for certain pathogens like Chlamydia trachomatis (Ct), Ureaplasma urealyticum, Neisseria gon-orrhoeae, herpes simplex virus types 1 and 2 (HSV-1/2), and human papillomavirus (HPV)